The The five-year project is funded by the
According to a release, this study will use a risk-diluted approach for rapid development and testing of molecularly-targeted imaging agents in phase 0 microdosing studies. The microdosing studies are designed to evaluate imaging of specific targets.
"Targeting an evaluation of imaging in early human surgical trials will allow us to efficiently assess potential candidates for further development," says Dr.
The first agent will be an Affibody molecule targeted to the epidermal growth factor receptor (EGFR), which is overexpressed in a broad range of cancers.
"The use of Affibody's proprietary molecules for optical imaging represents an exciting extension of our technology," says Dr.
"Imaging agents will be conjugated with IRDye 800CW (a near- infrared fluorescent dye developed by LI-COR), and compounds will be produced under cGMP conditions," says Dr.
Surgical signal detection and binding specificity will be the primary outcomes from the phase 0 trials. First-in-human studies with recurrent high-grade brain tumor patients will be pursued at
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its proprietary technology platforms: Affibody molecules and Albumod.
LI-COR Biosciences develops the highest quality fundamental research tools for cellular and molecular biology and environmental sciences, based on the core technologies of light, optics and electronics.
((Comments on this story may be sent to firstname.lastname@example.org))
The five-year project is funded by the